Dear Health Care Provider,

Since its approval in 1993,¹ Pulmozyme has been a cornerstone of cystic fibrosis (CF) therapy.² Today I would like to inform you that Pulmozyme has been approved for use with the eRapid Nebulizer System, which delivers shorter treatment times compared to conventional jet nebulizers.*³ ⁴ It is also small, portable, and quiet.³ ⁵

A phase IV study was done to evaluate comparable efficacy and safety of the PARI eRapid Nebulizer System, which is now a part of the approved list of nebulizers that deliver Pulmozyme treatments. A full list of nebulizer systems that have been approved for use with Pulmozyme is listed below:

### Approved nebulizers and compressors

<table>
<thead>
<tr>
<th>Jet Nebulizers</th>
<th>Compressors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hudson T Up-draft II® with</td>
<td>Pulmo-Aide®</td>
</tr>
<tr>
<td>Marquest Acorn II® with</td>
<td>Pulmo-Aide®</td>
</tr>
<tr>
<td>PARI LC® Plus with</td>
<td>PARI PRONEB®</td>
</tr>
<tr>
<td>PARI BABY™ with</td>
<td>PARI PRONEB®</td>
</tr>
<tr>
<td>Durable Sidestream® with</td>
<td>MOBILAIRE™</td>
</tr>
<tr>
<td>Durable Sidestream® with</td>
<td>Porta-Neb®</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nebulizer System</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PARI eRapid™ Nebulizer System</td>
<td>†</td>
</tr>
</tbody>
</table>

¹ Patients who are unable to inhale or exhale orally throughout the entire nebulization period may use the PARI BABY™ nebulizer.

‡ Consisting of the eRapid™ Nebulizer Handset with eBase™ Controller.

### Coverage and reimbursement

Gaining access to the eRapid Nebulizer System may involve reimbursement challenges and the eRapid Nebulizer System may not be approved by many payers. Patients who have coverage may encounter significant out-of-pocket costs and patients who do not have coverage may expect to pay full retail price.

For more information on the eRapid Nebulizer System:

Call PARI at (866) 335-6943 or visit www.pari.com

For more information on Pulmozyme, please speak with your local Genentech representative or contact Genentech at 1-800-821-8590.

Sincerely,

Will Chou, M.D.
Medical Director
Genentech USA

---

© 2014 Genentech USA, Inc., So. San Francisco, CA    PUL/112114/0028    12/14

---

**INDICATION**

Pulmozyme (dornase alfa) is indicated for daily administration in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.

**IMPORTANT SAFETY INFORMATION**

- Pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any component of the product.
- The most common adverse reactions associated with the use of Pulmozyme include: voice alteration, pharyngitis, rash, laryngitis, chest pain, conjunctivitis, rhinitis, decrease in FVC of ≥ 10%, fever, dyspepsia, and dyspnea. There have been no reports of anaphylaxis attributed to the administration of Pulmozyme. Mild to moderate urticaria and mild skin rash have been observed and have been transient.

**References:**